CN103827093B - 5-羟基-1h-咪唑-4-甲酰胺水合物的晶体和5-羟基-1h-咪唑-4-甲酰胺·3/4水合物的晶体及其制造方法 - Google Patents

5-羟基-1h-咪唑-4-甲酰胺水合物的晶体和5-羟基-1h-咪唑-4-甲酰胺·3/4水合物的晶体及其制造方法 Download PDF

Info

Publication number
CN103827093B
CN103827093B CN201280047308.0A CN201280047308A CN103827093B CN 103827093 B CN103827093 B CN 103827093B CN 201280047308 A CN201280047308 A CN 201280047308A CN 103827093 B CN103827093 B CN 103827093B
Authority
CN
China
Prior art keywords
imidazole
hydrate
carboxamide
hydroxy
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280047308.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN103827093A (zh
Inventor
藤本泰典
桥本智宏
林克幸
田中智之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN103827093A publication Critical patent/CN103827093A/zh
Application granted granted Critical
Publication of CN103827093B publication Critical patent/CN103827093B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201280047308.0A 2011-09-28 2012-09-28 5-羟基-1h-咪唑-4-甲酰胺水合物的晶体和5-羟基-1h-咪唑-4-甲酰胺·3/4水合物的晶体及其制造方法 Expired - Fee Related CN103827093B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011213500 2011-09-28
JP2011-213501 2011-09-28
JP2011-213500 2011-09-28
JP2011213501 2011-09-28
PCT/JP2012/075106 WO2013047758A1 (ja) 2011-09-28 2012-09-28 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド水和物の結晶及び５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の結晶及びその製造方法

Publications (2)

Publication Number Publication Date
CN103827093A CN103827093A (zh) 2014-05-28
CN103827093B true CN103827093B (zh) 2016-06-15

Family

ID=47995783

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280047308.0A Expired - Fee Related CN103827093B (zh) 2011-09-28 2012-09-28 5-羟基-1h-咪唑-4-甲酰胺水合物的晶体和5-羟基-1h-咪唑-4-甲酰胺·3/4水合物的晶体及其制造方法

Country Status (13)

Country Link
US (2) US9108928B2 (enExample)
EP (1) EP2762469B1 (enExample)
KR (1) KR101970509B1 (enExample)
CN (1) CN103827093B (enExample)
AU (1) AU2012317424B2 (enExample)
BR (1) BR112014007436A2 (enExample)
CA (1) CA2850196A1 (enExample)
IL (2) IL231677A (enExample)
IN (1) IN2014CN02346A (enExample)
MX (1) MX354498B (enExample)
RU (2) RU2672560C1 (enExample)
SG (1) SG11201400974VA (enExample)
WO (1) WO2013047758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007436A2 (pt) 2011-09-28 2017-04-04 Fujifilm Corp cristal de 5-hidróxi-1h-imidazola-4-carboxamida:3/4 hidrato, método para a produção do mesmo e cristal de 5-hidróxi-1h-imidazola-4-carboxamida hidrato
BR112015015282A2 (pt) * 2013-01-15 2017-07-11 Fujifilm Corp sulfato de 5 - hidróxi - 1h - imidazol - 4 - carboxamida
RU2672872C2 (ru) 2014-01-10 2018-11-20 Фуджифилм Корпорэйшн Способ и устройство для прогнозирования эффективной дозы или восприимчивости к 5-гидрокси-1н-имидазол-4-карбоксамиду, способ определения количества ксантозинмонофосфата, а также средство и способ для лечения миелодиспластического синдрома
WO2018051971A1 (ja) * 2016-09-13 2018-03-22 富士フイルム株式会社 Ｍｌｌ関連白血病の予防または治療のための医薬、方法、使用及び化合物
WO2019082898A1 (ja) 2017-10-27 2019-05-02 富士フイルム株式会社 ５－ヒドロキシ－１ｈ－イミダゾール－４－カルボキサミド・３／４水和物の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159777A1 (en) * 1984-03-05 1985-10-30 Sumitomo Pharmaceuticals Company, Limited Stabilized 4-carbamoyl-imidazolium-5-olate
CN101395141A (zh) * 2006-02-24 2009-03-25 莱西肯医药有限公司 咪唑基化合物，包含其的组合物和它们的使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
JPS5625165A (en) * 1979-08-08 1981-03-10 Sumitomo Chem Co Ltd Novel imidazole derivative
JPS5824569A (ja) 1981-08-05 1983-02-14 Sumitomo Chem Co Ltd イミダゾ−ル誘導体の精製方法
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
CA2152863A1 (en) 1994-07-26 1996-01-27 Yeun-Kwei Han Preparation of acyclovir
US5567816A (en) 1994-07-26 1996-10-22 Syntex (U.S.A.) Inc. Preparation of acyclovir using 1,3 dioxolane
DK1320527T3 (da) 2000-09-29 2008-12-01 Basf Se Fremgangsmåde til fremstilling af 1-substituerede 5-chlor-4-methylpytrazoler
JP2002265601A (ja) 2001-03-07 2002-09-18 Rikogaku Shinkokai イミド樹脂
CA2597896A1 (en) * 2005-02-16 2006-08-24 Solvay Pharmaceuticals B.V. 1h-imidazole derivatives as cannabinoid cb2 receptor modulators
JP5266010B2 (ja) * 2007-09-14 2013-08-21 富士フイルム株式会社 ４−カルバモイル−５−ヒドロキシ−イミダゾール誘導体のスルホン酸塩化合物
KR100982720B1 (ko) * 2008-02-04 2010-09-17 주식회사 파마코스텍 4-카르바모일-1-β-Ｄ-리보푸라노실이미다졸륨-5-올레이트의 생산을 위한 중간체로서의 2-아미노말론아미드의제조방법
TWI573791B (zh) 2011-09-28 2017-03-11 富士軟片股份有限公司 ５－羥基－１ｈ－咪唑－４－甲醯胺．３／４水合物及其結晶之製造方法
BR112014007436A2 (pt) 2011-09-28 2017-04-04 Fujifilm Corp cristal de 5-hidróxi-1h-imidazola-4-carboxamida:3/4 hidrato, método para a produção do mesmo e cristal de 5-hidróxi-1h-imidazola-4-carboxamida hidrato

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0159777A1 (en) * 1984-03-05 1985-10-30 Sumitomo Pharmaceuticals Company, Limited Stabilized 4-carbamoyl-imidazolium-5-olate
CN101395141A (zh) * 2006-02-24 2009-03-25 莱西肯医药有限公司 咪唑基化合物，包含其的组合物和它们的使用方法

Also Published As

Publication number Publication date
IL231677A0 (en) 2014-05-28
IL231677A (en) 2017-01-31
EP2762469A4 (en) 2015-01-14
KR20140069052A (ko) 2014-06-09
US20150315156A1 (en) 2015-11-05
RU2630682C2 (ru) 2017-09-12
NZ622928A (en) 2015-04-24
BR112014007436A2 (pt) 2017-04-04
US20140275568A1 (en) 2014-09-18
AU2012317424B2 (en) 2017-05-18
IN2014CN02346A (enExample) 2015-06-19
HK1197406A1 (zh) 2015-01-16
AU2012317424A1 (en) 2014-04-17
US9108928B2 (en) 2015-08-18
MX354498B (es) 2018-03-08
CN103827093A (zh) 2014-05-28
WO2013047758A1 (ja) 2013-04-04
CA2850196A1 (en) 2013-04-04
EP2762469B1 (en) 2016-11-23
MX2014003638A (es) 2014-05-21
RU2014111810A (ru) 2015-11-10
EP2762469A1 (en) 2014-08-06
IL246754A (en) 2017-08-31
KR101970509B1 (ko) 2019-04-19
RU2672560C1 (ru) 2018-11-16
US9567303B2 (en) 2017-02-14
AU2012317424A8 (en) 2014-07-03
SG11201400974VA (en) 2014-09-26

Similar Documents

Publication Publication Date Title
CN103827093B (zh) 5-羟基-1h-咪唑-4-甲酰胺水合物的晶体和5-羟基-1h-咪唑-4-甲酰胺·3/4水合物的晶体及其制造方法
CN103930414B (zh) 7-{(3s,4s)-3-[(环丙基氨基)甲基]-4-氟吡咯烷-1-基}-6-氟-1-(2-氟乙基)-8-甲氧基-4-氧-1,4-二氢喹啉-3-羧酸晶体
US10011591B2 (en) Crystalline form of afatinib dimaleate
CN101774969B (zh) 硫酸伊伐布雷定及其i型结晶的制备方法
JP5905614B2 (ja) ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド・３／４水和物の製造方法及びその結晶の製造方法
CN101939314A (zh) 3-吡咯取代的2-吲哚酮的多晶型物
CZ2014708A3 (cs) Soli Bedaquilinu
HK1197406B (en) Crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate, crystal of 5-hydroxy-1h-imidazole-4-carboxamide 3/4 hydrate, and method for producing same
CN107382975B (zh) 氟代芳胺嘧啶化合物及其盐的结晶形式
CN110818817A (zh) 一种舒更葡糖钠二苯基氧磷衍生物杂质及其制备方法
CN104903299B (zh) 5-羟基-1h-咪唑-4-甲酰胺的硫酸盐
NZ622928B2 (en) Crystal of 5-hydroxy-1h-imidazole-4-carboxamide·3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1 h-imidazole-4-carboxamide hydrate
US9840506B2 (en) Crystal of doripenem, and preparation method therefor
CN101084222A (zh) 2－甲基－4－(4－甲基－1－哌嗪基)－10H－噻吩并[2,3－b][1,5]苯并二氮杂䓬及其盐的合成
TW202221002A (zh) 一種btk降解劑的製備方法
WO2016034150A1 (zh) 博舒替尼及其结晶的制备方法
CZ2015391A3 (cs) Sůl bedaquilinu s kyselinou citronovou
JP2013082706A (ja) ５−ヒドロキシ−１ｈ−イミダゾール−４−カルボキサミド水和物の結晶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1197406

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1197406

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160615

Termination date: 20200928

CF01 Termination of patent right due to non-payment of annual fee